Published in F1000Res on June 30, 2016
Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol (2009) 7.04
BRAF mutation in metastatic colorectal cancer. N Engl J Med (2009) 3.68
Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma. Clin Cancer Res (2012) 2.46
Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials. Ann Oncol (2014) 2.31
Implementing personalized cancer genomics in clinical trials. Nat Rev Drug Discov (2013) 2.07
EGFR testing in lung cancer is ready for prime time. Lancet Oncol (2009) 1.49
Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer. J Clin Oncol (2005) 1.45
Medical management of malignant melanoma. Aust Prescr (2015) 1.33
Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer. Br J Cancer (2015) 1.28
BRAF-mutated metastatic colorectal cancer between past and future. Br J Cancer (2015) 0.88
The efficacy of additional bevacizumab to cytotoxic chemotherapy regimens for the treatment of colorectal cancer: an updated meta-analysis for randomized trials. Cancer Biother Radiopharm (2013) 0.88
Reply: Comment on 'Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal-antibody therapy for RAS wild-type metastatic colorectal cancer'. Br J Cancer (2015) 0.80